Канада - английский - Health Canada

mekos laboratories aps - nickel sulfate; wool alcohols; neomycin sulfate; potassium dichromate; benzocaine; dibucaine hydrochloride; tetracaine hydrochloride; amyl cinnamal; isoeugenol; cinnamaldehyde; eugenol; cinnamyl alcohol; hydroxycitronellal; geraniol; oak moss; rosin; epoxy resin; clioquinol; chloroquinaldol; peruvian balsam; ethylenediamine dihydrochloride; cobaltous chloride; p-tert-butylphenol formaldehyde resin; methylparaben; ethyl paraben; propylparaben; butylparaben; benzyl paraben; diphenylguanidine; zinc dibutyldithiocarbamate; n-cyclohexyl-n'-phenyl-para-phenylenediamine; methylchloroisothiazolinone; quaternium-15; mercaptobenzothiazole; p-phenylenediamine; (morpholinothio)benzothiazole; dithiobis (benzothiazole); thimerosal; thiram; bis(1-piperidylthiocarbonyl)disulfide; zinc diethyldithiocarbamate; n-isopropyl-n'-phenyl-para-phenylenediamine; n,n'-diphenyl-para-phenylenediamine; tetramethylthiuram monosulfide; disulfiram; n-cyclohexyl-2-benzothiazolesulfenamide; n-hydroxymethylsuccinimide - patch - 0.16mg; 0.81mg; 0.19mg; 0.019mg; 0.364mg; 0.073mg; 0.073mg; 0.015mg; 0.015mg; 0.034mg; 0.034mg; 0.054mg; 0.054mg; 0.07mg; 0.07mg; 0.69mg; 0.041mg; 0.08mg; 0.08mg; 0.65mg; 0.041mg; 0.016mg; 0.041mg; 0.16mg; 0.16mg; 0.16mg; 0.16mg; 0.16mg; 0.068mg; 0.068mg; 0.025mg; 0.0032mg; 0.081mg; 0.061mg; 0.073mg; 0.02mg; 0.02mg; 0.0065mg; 0.005mg; 0.005mg; 0.068mg; 0.01mg; 0.025mg; 0.005mg; 0.005mg; 0.02mg; 0.15mg - nickel sulfate 0.16mg; wool alcohols 0.81mg; neomycin sulfate 0.19mg; potassium dichromate 0.019mg; benzocaine 0.364mg; dibucaine hydrochloride 0.073mg; tetracaine hydrochloride 0.073mg; amyl cinnamal 0.015mg; isoeugenol 0.015mg; cinnamaldehyde 0.034mg; eugenol 0.034mg; cinnamyl alcohol 0.054mg; hydroxycitronellal 0.054mg; geraniol 0.07mg; oak moss 0.07mg; rosin 0.69mg; epoxy resin 0.041mg; clioquinol 0.08mg; chloroquinaldol 0.08mg; peruvian balsam 0.65mg; ethylenediamine dihydrochloride 0.041mg; cobaltous chloride 0.016mg; p-tert-butylphenol formaldehyde resin 0.041mg; methylparaben 0.16mg; ethyl paraben 0.16mg; propylparaben 0.16mg; butylparaben 0.16mg; benzyl paraben 0.16mg; diphenylguanidine 0.068mg; zinc dibutyldithiocarbamate 0.068mg; n-cyclohexyl-n'-phenyl-para-phenylenediamine 0.025mg; methylchloroisothiazolinone 0.0032mg; quaternium-15 0.081mg; mercaptobenzothiazole 0.061mg; p-phenylenediamine 0.073mg; (morpholinothio)benzothiazole 0.02mg; dithiobis (benzothiazole) 0.02mg; thimerosal 0.0065mg; thiram 0.005mg; bis(1-piperidylthiocarbonyl)disulfide 0.005mg; zinc diethyldithiocarbamate 0.068mg; n-isopropyl-n'-phenyl-para-phenylenediamine 0.01mg; n,n'-diphenyl-para-phenylenediamine 0.025mg; tetramethylthiuram monosulfide 0.005mg; disulfiram 0.005mg; n-cyclohexyl-2-benzothiazolesulfenamide 0.02mg; n-hydroxymethylsuccinimide 0.15mg - allergenic extracts

Австралия - английский - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 119.47 mg (equivalent: imatinib, qty 100 mg) - capsule, hard - excipient ingredients: crospovidone; sodium stearylfumarate; gelatin; titanium dioxide; purified water; iron oxide yellow; sodium lauryl sulfate; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 59.735 mg (equivalent: imatinib, qty 50 mg) - capsule, hard - excipient ingredients: sodium stearylfumarate; gelatin; sodium lauryl sulfate; titanium dioxide; purified water; iron oxide yellow; crospovidone; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; iron oxide red; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 477.88 mg - capsule, hard - excipient ingredients: crospovidone; purified water; titanium dioxide; sodium stearylfumarate; sodium lauryl sulfate; gelatin; iron oxide yellow; iron oxide black; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 59.735 mg (equivalent: imatinib, qty 50 mg) - capsule, hard - excipient ingredients: gelatin; titanium dioxide; iron oxide yellow; sodium lauryl sulfate; sodium stearylfumarate; purified water; crospovidone; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; iron oxide red; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 477.88 mg (equivalent: imatinib, qty 400 mg) - capsule, hard - excipient ingredients: purified water; titanium dioxide; sodium lauryl sulfate; gelatin; sodium stearylfumarate; crospovidone; iron oxide yellow; iron oxide black; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 119.47 mg (equivalent: imatinib, qty 100 mg) - capsule, hard - excipient ingredients: purified water; gelatin; crospovidone; titanium dioxide; iron oxide yellow; sodium lauryl sulfate; sodium stearylfumarate; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)

Австралия - английский - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pregabalin, quantity: 25 mg - capsule, hard - excipient ingredients: purified talc; titanium dioxide; sodium lauryl sulfate; lactose monohydrate; gelatin; purified water; maize starch - pregabalin-drla (pregabalin) is indicated for the treatment of neuropathic pain in adults.,pregabalin-drla (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pregabalin, quantity: 75 mg - capsule, hard - excipient ingredients: iron oxide red; gelatin; lactose monohydrate; titanium dioxide; maize starch; sodium lauryl sulfate; purified water; purified talc - pregabalin-drla (pregabalin) is indicated for the treatment of neuropathic pain in adults.,pregabalin-drla (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pregabalin, quantity: 300 mg - capsule, hard - excipient ingredients: iron oxide red; purified talc; gelatin; lactose monohydrate; sodium lauryl sulfate; maize starch; titanium dioxide; purified water - pregabalin-drla (pregabalin) is indicated for the treatment of neuropathic pain in adults.,pregabalin-drla (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.